Press Release Archives

Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders     August 1, 2025   WARREN, N.J., Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today released a letter to stockholders.   Dear Fellow Stockholders,   Tevogen has rapidly evolved from a biotechnology innovator into a dynamic enterprise expandingContinue reading “Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders”

Tevogen Bio to Accept $1 Million Additional Grant Funding for AI Expansion   Funds will support advancement of Tevogen.AI, the Company’s artificial intelligence–driven drug discovery initiative. The $1 million is part of up to $10 million in previously announced non‑dilutive grant funding from KRHP LLC.   August 1, 2025   WARREN, N.J., Tevogen Bio HoldingsContinue reading “Tevogen Bio to Accept $1 Million Additional Grant Funding for AI Expansion”

Tevogen Highlights 74% Insider Ownership, Reinforcing Long-Term Vision     July 30, 2025   WARREN, N.J., Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today highlighted the Company’s significant insider ownership of outstanding common stock, as most recently reported on July 10, 2025, on Form 8-K filed with the Securities and Exchange Commission.  Continue reading “Tevogen Highlights 74% Insider Ownership, Reinforcing Long-Term Vision”

Tevogen.AI Applauds U.S. Government’s AI Action Plan; Reaffirms Commitment to Accelerating AI Innovation in Healthcare     July 28, 2025   WARREN, N.J., Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today welcomes the White House’s release of “Winning the Race: America’s AI Action Plan”, issued July 23, 2025. The Company applauds the federalContinue reading “Tevogen.AI Applauds U.S. Government’s AI Action Plan; Reaffirms Commitment to Accelerating AI Innovation in Healthcare”

Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides     July 18, 2025   WARREN, N.J., Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) announced today that the International Bureau of the World Intellectual Property Organization (WIPO) has published its international patent application (Publication No. WO 2025/129197) titled, “Systems andContinue reading “Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides”

Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility     July 17, 2025   WARREN, N.J., Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced the signing of a letter of intent to lease a 17,428-square-foot facility in New Jersey. The facility, formerly occupied by Pfizer (NYSE: PFE) andContinue reading “Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility”

Tevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell Alpha Launch   Advanced algorithms aim to reduce trial planning timelines, accelerating time-to-market for new therapies Initiative to support Tevogen Bio’s ExacTcell™ pipeline with a goal of enhancing commercial viability and shareholder value   July 16, 2025   WARREN, N.J., Tevogen (“Tevogen Bio Holdings Inc.”Continue reading “Tevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell Alpha Launch”

Tevogen.AI Builds Alpha Version of PredicTcell Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development Costs   AI’s model drastically reduces target analysis and has the potential to generate billions in cost savings across the healthcare system by streamlining early-stage drug discovery, reducingContinue reading “Tevogen.AI Builds Alpha Version of PredicTcell Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development Costs”

Tevogen’s New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate Innovation   CEO’s personal contribution fully funds build-out and first-year operations Doubled HQ footprint centralizes cross-functional teams, including research, regulatory affairs, and the expanding Tevogen.AI initiative     July 10, 2025   WARREN, N.J., Tevogen (“Tevogen Bio Holdings Inc.” or “Company”)Continue reading “Tevogen’s New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate Innovation”

Tevogen CEO Contributes to Build-Out and First-Year Operations of New Headquarters     June 30, 2025   WARREN, N.J., Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that founder and Chief Executive Officer, Ryan Saadi, M.D., M.P.H., has personally contributed $500,000 towards the build-out and first-year operating costs of Tevogen’s new corporateContinue reading “Tevogen CEO Contributes to Build-Out and First-Year Operations of New Headquarters”